Enanta Pharmaceuticals
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Enanta Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#467 of 15,742 sponsors by registered trial count).
Enanta Pharmaceuticals: 36 sponsored US clinical trials, 1 recruiting.
Enanta Pharmaceuticals sponsors 36 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 32 completed. 0 of these trials are in Phase 3-4 (later-stage) and 36 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is RSV Infection, with 3 trials.
Top-decile sponsor footprint
Enanta Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#467 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
32 of 35 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (91.4%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
36 total, page 1 of 1
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of EDP-978 in Healthy Adults
NCT07540910
A Study to Evaluate the Drug-Drug Interaction of EDP-323 With Midazolam, Caffeine, and Rosuvastatin in Healthy Participants
NCT06917508
A Drug-Drug Interaction Study to Evaluate the Effects of Itraconazole, Carbamazepine, Quinidine and Fluconazole on the Pharmacokinetics and Safety of EDP-323.
NCT06847464
A Study to Investigate the Effects of Zelicapavir (EDP-938) on QTc Interval in Healthy Adults
NCT06601192
A Study of EDP-938 in Non-hospitalized Adults With RSV Who Are at High Risk for Complications.
NCT05568706
A Study to Evaluate EDP-235 in Non-hospitalized Adults With COVID-19
NCT05616728
Drug-Drug Interaction Study Between EDP-235, Itraconazole, Carbamazepine and Quinidine in Healthy Subjects.
NCT05594602
Drug-Drug Interaction Study Between EDP-235, Midazolam, Caffeine and Rosuvastatin in Healthy Subjects
NCT05594615
A Study of EDP-323 in Healthy Subjects
NCT05587478
A Study to Evaluate EDP 938 Regimens in Children With RSV
NCT04816721
A Study of EDP-235 in Healthy Subjects
NCT05246878
Effects of EDP-938 in Hematopoietic Cell Transplant Recipients Infected With Respiratory Syncytial Virus of the Upper Respiratory Tract
NCT04633187
Absorption, Metabolism, and Excretion (AME) Study of [14C]EDP-938 in Healthy Male Subjects
NCT04927793
Drug-Drug Interaction Study Between Fluconazole and EDP-938 in Healthy Subjects
NCT04871724
Drug-Drug Interaction Study Between EDP-514, Itraconazole, Carbamazepine, and Quinidine in Healthy Subjects
NCT04783753
Drug-Drug Interaction Study Between EDP-938, Tacrolimus, Dabigatran, Rosuvastatin and Midazolam in Healthy Subjects
NCT04498741
A Randomized, Double-blind Study to Assess the Safety and Efficacy of EDP-305 in Subjects With Liver-biopsy Proven NASH
NCT04378010
A Study to Assess EDP-938 for the Treatment of Acute Upper Respiratory Tract Infection With Respiratory Syncytial Virus in Adult Subjects
NCT04196101
A Study of EDP-514 in Healthy Subjects (Part 1) and Patients With Chronic Hepatitis B Virus Infection (Part 2)
NCT04008004
Drug-Drug Interaction Study Between EDP-938, Itraconazole, Rifampin, and Quinidine in Healthy Subjects
NCT03755778
A Drug-drug Interaction Study to Investigate the Effect of Coadministration of EDP-305 on the PK of a Combined Oral Contraceptive in Healthy Female Subjects
NCT03783897
Drug-Drug Interaction Study Between EDP-938, Cyclosporine and Prednisone in Healthy Adult Subjects
NCT03750383
Absorption, Metabolism and Excretion (AME) Study of [14C]EDP-305 in Healthy Male Subjects
NCT03748628
Drug-drug Interaction Study Between EDP-305, Fluconazole and Quinidine in Healthy Volunteers
NCT03610945
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Non-Alcoholic Steatohepatitis
NCT03421431
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Primary Biliary Cholangitis
NCT03394924
A Study of EDP-938 in Healthy Subjects
NCT03384823
Drug-drug Interaction Study Between EDP-305, Intraconazole and Rifampin in Healthy Volunteers
NCT03213145
A Study of EDP-305 in Subjects With Mild and Moderate Hepatic Impairment Compared With Normal Healthy Volunteers
NCT03207425
Drug-drug Interaction Study Between EDP-305, Midazolam, Caffeine and Rosuvastatin in Healthy Volunteers.
NCT03187496
A Study of EDP 305 in Healthy Subjects and Subjects With Presumptive NAFLD
NCT02918929
Evaluation of the Safety, Tolerability, and Pharmacokinetics of Multiple Oral Doses of EDP-788
NCT02255968
Evaluation of the Safety and Pharmacokinetics of a Single Oral Dose of EDP-788
NCT01999725
Proof of Concept Study for Safety and Efficacy of EDP239 in Hepatitis C Subjects
NCT01856426
Multiple Ascending-Dose Study of EDP 322 in Healthy Adult Volunteers
NCT00990145
Safety and Pharmacokinetics of Ascending Single Oral Doses of EDP-322 in Nonfasting and Fasting Healthy Volunteers
NCT00989872
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 28 |
| Phase 2 | 8 |
What is open in the Enanta Pharmaceuticals pipeline
1 recruiting of 36 indexed (3% open); 32 completed (89%).
Phase mix: 0 late (III/IV) vs 36 early (I/II) (early-phase heavy).
Top condition: RSV Infection (3 trials), 8 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Enanta Pharmaceuticals: open-pipeline peers nationwide
Peers matched on 36 registered trials and 3% open enrollment, not the therapeutic-area sidebar.
Enanta Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 36 trials (± recruiting share)
- Acorda Therapeutics · 36 trials · 0% recruiting
- Baystate Medical Center · 36 trials · 17% recruiting
- Eastern Virginia Medical School · 36 trials · 17% recruiting
- MacroGenics · 36 trials · 11% recruiting
Sponsors near 3% open enrollment (± trial volume)
- Eastern Cooperative Oncology Group · 3% recruiting · 141 trials
- Appalachian State University · 3% recruiting · 37 trials
- Bracco Diagnostics · 3% recruiting · 37 trials
- Janssen Scientific Affairs · 3% recruiting · 37 trials
Related
What to do with this Enanta Pharmaceuticals page
36 registered trials is a research-attention snapshot, not an endorsement of Enanta Pharmaceuticals or any single study.
- 1 of Enanta Pharmaceuticals's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- RSV Infection is the condition Enanta Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See RSV Infection trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Enanta Pharmaceuticals pipeline card: 36 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.